{"id":2,"date":"2023-10-07T12:04:26","date_gmt":"2023-10-07T04:04:26","guid":{"rendered":"https:\/\/cytoarm.com\/?page_id=2"},"modified":"2025-08-22T14:34:07","modified_gmt":"2025-08-22T06:34:07","slug":"home","status":"publish","type":"page","link":"https:\/\/cytoarm.com\/zh\/","title":{"rendered":"Home"},"content":{"rendered":"\n
\n
\n
\"Armed-T,<\/div>\n\n\n\n
\"Banner1<\/div>\n<\/div><\/div><\/div>\n\n\n\n
\n
\"Banner2<\/div>\n\n\n\n
\"Banner2<\/div>\n<\/div><\/div><\/div>\n\n\n\n
\n
\"Armed-T<\/div>\n\n\n\n
\"Banner3<\/div>\n<\/div><\/div><\/div>\n<\/div><\/div>
<\/div>
<\/div>
<\/div>
<\/div><\/div><\/div>\n\n\n\n
\n
\n

BsAb Armed-T\u2122 Therapy Platform <\/h1>\n\n\n\n

Revolutionizing T Cell Cancer Treatment<\/em><\/h2>\n\n\n\n
CytoArm\u2019s innovative BsAb Armed-T<\/mark>\u2122<\/strong> therapy platform utilizes non-viral bi-functional antibodies (BsAb) to empower T cells in targeting tumor cells effectively. This pioneering approach enables adaptable cancer treatments across various oncological conditions, potentially addressing limitless diseases<\/h5>\n\n\n\n

CytoArm’s Non-Viral BsAb Armed-T\u2122<\/strong> therapy is a platform that Adaptable and Targeted Cancer Treatments covering over 50 diseases <\/h2>\n<\/div>\n\n\n\n
\n
\n
\n
\"Cytoarm<\/div>\n\n\n\n
Our Bi-functional antibody (BsAb) activates T cells to target tumor markers<\/div>\n\n\n\n
Our BsAb Antibody<\/span><\/span>\"Swap<\/span><\/span><\/a><\/div>\n<\/div>\n\n\n\n
\n
\"Cytoarm<\/div>\n\n\n\n
BsAb Armed-T\u2122<\/strong><\/mark> cells provide promising adaptable cancer treatments<\/div>\n\n\n\n
Our Armed-T Technique<\/span><\/span>\"Swap<\/span><\/span><\/a><\/div>\n<\/div>\n\n\n\n
\n
\"Cytoarm<\/div>\n\n\n\n
CytoArm can create BsAb Armed-T\u2122<\/strong><\/mark> products to cover more than
50 diseases<\/div>\n\n\n\n
Our Armed-T Pipelines<\/span><\/span>\"Swap<\/span><\/span><\/a><\/div>\n<\/div>\n <\/div><\/div>\n<\/div>\n <\/div><\/section>\n\n\n\n
\n
\n

News<\/h2>\n\n\n\n
\n\n
\"Armed-T<\/span><\/a>\n\n\n
2024-10-14<\/div>\n\n\n
CytoArm Patent Overview (Updated)<\/a><\/div><\/div>\n\n\nContinue Reading: CytoArm Patent Overview (Updated)<\/span><\/a><\/div>\n<\/div>\n\n<\/article>
\n\n
\"Dall\u00b7e<\/span><\/a>\n\n\n
2024-07-15<\/div>\n\n\n
CytoArm Licenses CD19 Armed-T cell for Blood Cancer Drug Development to SL-LINK Company<\/a><\/div><\/div>\n\n\nContinue Reading: CytoArm Licenses CD19 Armed-T cell for Blood Cancer Drug Development to SL-LINK Company<\/span><\/a><\/div>\n<\/div>\n\n<\/article>
\n\n
\"Bio<\/span><\/a>\n\n\n
2024-05-20<\/div>\n\n\n
Join us at BIO 2024, June 3-6 in San Diego<\/a><\/div><\/div>\n\n\nContinue Reading: Join us at BIO 2024, June 3-6 in San Diego<\/span><\/a><\/div>\n<\/div>\n\n<\/article><\/div>